Navigation Links
Research identifies potential new use for cancer treatment
Date:3/15/2010

Drugs increasingly used to treat cancer could have a major impact on a wide range of infectious diseases, according to new research.

Anti-angiogenic drugs are used to try and prevent cancers from stimulating the growth of the blood vessels they need to survive and grow.

New research by the Centre for Immunology and Infection at the University of York suggests the same drugs may help in the treatment of other diseases including visceral leishmaniasis which kills 70,000 people worldwide every year.

The findings, published online today by the Journal of Clinical Investigation, show that anti-angiogenic drugs can improve the structure of tissues where immune responses are generated and which are often destroyed by chronic infection or inflammation.

The resulting improvement in the immune response can increase the effectiveness of conventional treatments for leishmaniasis, allowing doctors to use lower doses of existing drugs that otherwise have harmful side effects.

Professor Paul Kaye, Director of the Centre for Immunology and Infection, said: "While our research has focused on leishmaniasis the findings could have implications for a range of globally important diseases.

"It is particularly exciting that this potential has been discovered in a class of drugs that are already well-established in clinical practice.

"Our research also identifies ways that anti-angiogenic drugs might be used more effectively in the treatment of cancers."

The research was funded by the Medical Research Council and the Wellcome Trust.

These findings have led to further research, supported by Yorkshire Cancer Research, into the potential use of anti-angiogenic drugs as a "preconditioning agent" in the treatment of melanoma.


'/>"/>

Contact: James Reed
jr576@york.ac.uk
44-190-443-2029
University of York
Source:Eurekalert

Page: 1

Related medicine news :

1. Researchers discover chemical that may protect hearts of muscular dystrophy patients
2. Nuvo Research enrolls first patient in Phase 2 WF10 allergic rhinitis trial
3. Researchers recommend curriculum on unhealthy substance use
4. Using new approach, Mayo Clinic researchers find level of gene alters risk of Alzheimers disease
5. CEMPER.COM Launches New Link Research Tool Version with New Data Source Support for SeoMoz, Sistrix, SEMrush and Majestic SEO
6. Carnegie Mellon research provides insight into brains decision-making process
7. Researchers discover brain tumors grow-or-go switch
8. Get up, get out and go: NC State research tackles childhood obesity
9. A new beat in heart research
10. Harvard School of Public Health unveils comprehensive, public online library of firearms research
11. Penn researcher, Louis J. Soslowsky, PhD, winner of the AAOS Kappa Delta Ann Doner Vaughan Award
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/29/2017)... ... 29, 2017 , ... Full Contact K9, an Atlanta-based dog services provider, has ... that assists dog owners in creating legally-enforceable pet trusts for their canine companions. ... step to protect their new companion. Says Evan Dunbar, CEO of Full Contact K9, ...
(Date:3/29/2017)... ... March 30, 2017 , ... Youth Futures International (YFI) premiered its Serve, Learn, ... school and college students who have participated in the program every summer. The ... now accepting applications for enrollment. Visit http://www.ghana.yfiexperience.org to learn more. , ...
(Date:3/29/2017)... ... March 29, 2017 , ... Wells ... for attending prescribers at the upcoming World Congress, in Hollywood Florida April 6-8, ... been recognized as the visionary leader in the training of physicians, scientists, and ...
(Date:3/29/2017)... ... March 29, 2017 , ... Based on research from Guardian’s ... face in trying to balance both short-term and long-term benefits demands. Are ... the growing complexity, companies are finding that the short-term strategies used to control ...
(Date:3/29/2017)... (PRWEB) , ... March 29, ... ... Manufacturer Alliance (GRMA) is growing as it continues developing an ANSI-approved, consensus-based ... industry. The organization, which plans to publish the first ANSI-approved GMP standard ...
Breaking Medicine News(10 mins):
(Date:3/29/2017)... , March 29, 2017  Zynex (OTCQB: ZYXI), an ... sale of non-invasive medical devices for pain management, stroke ... it will host the Company,s 2016 full-year investor webcast ... Time.) The Company expects to file its ... ...
(Date:3/29/2017)... N.J. , March 29, 2017  Glenmark ... results for GSP 301, an investigational fixed-dose combination ... (665 mcg) administered twice-daily as a nasal spray ... rhinitis. These results are from a recently completed ... of GSP 301 combination therapy versus mometasone, olopatadine ...
(Date:3/29/2017)... -- Maxor National Pharmacy Services, LLC ("Maxor"), a leading pharmacy ... Leah Bailey as General Counsel.  Bailey will serve as ... With more than 13 years of experience in ... health care, Bailey joins the Maxor team coming from ... the PBM, Specialty, and Mail Order business areas on ...
Breaking Medicine Technology: